Plasma neurofilament light levels show elevation two years prior to diagnosis of amyotrophic lateral sclerosis in the UK Biobank

References

• Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874–80.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson’s disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry. 2010;81:1008–13.
   PubMed Web of Science ®Google Scholar
• Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opin Biol Ther. 2018;18:25–35.
   PubMed Web of Science ®Google Scholar
• Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 2016;91:56–66.
   PubMed Web of Science ®Google Scholar
• Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec. 1970;167:379–87.
   PubMedGoogle Scholar
• Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–81.
   PubMed Web of Science ®Google Scholar
• Olsson B, Portelius E, Cullen NC, Sandelius A, Zetterberg H, Andreasson U, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76:318–25.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247–57.
   PubMed Web of Science ®Google Scholar
• Meyer T, Salkic E, Grehl T, Weyen U, Kettemann D, Weydt P, et al. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study. Eur J Neurol. 2023;30:1600–10.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732–9.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–9.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:538–48.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, O'Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, et al. Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 2021;97:e1466-74–e1474.
   Web of Science ®Google Scholar
• Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality. Pharmacogenomics 2005;6:639–46.
   PubMed Web of Science ®Google Scholar
• Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 2023;622:329–38.
   PubMed Web of Science ®Google Scholar
• Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Soft. 2011;42:1–28.
   Web of Science ®Google Scholar
• Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.
   PubMed Web of Science ®Google Scholar
• Vroling B, Heijl S. White paper: the helix pathogenicity prediction platform. arXiv preprint arXiv:210401033. 2021.
   Google Scholar
• Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381–97.
   PubMed Web of Science ®Google Scholar
• Kathryn Bush JN, C. Sudlow Definitions of Motor Neurone Disease and the Major Diagnostic Subtypes, UK Biobank Phase 1 Outcomes Adjudication. 2018.
   Google Scholar
• Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673–84.
   PubMed Web of Science ®Google Scholar
• Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, et al. Plasma NfL, clinical subtypes and motor progression in Parkinson’s disease. Parkinsonism Relat Disord. 2021;87:41–7.
   PubMed Web of Science ®Google Scholar
• Rostalski H, Korhonen V, Kuulasmaa T, Solje E, Kruger J, Gen F, et al. A novel genetic marker for the C9orf72 repeat expansion in the finnish population. J Alzheimers Dis. 2021;83:1325–32.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:453–6.
   PubMed Web of Science ®Google Scholar
• Williams JR, Fitzhenry D, Grant L, Martyn D, Kerr DA. Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database. BMC Neurol. 2013;13:160.
   PubMed Web of Science ®Google Scholar
• Kuffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51–7.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145:27–44.
   PubMed Web of Science ®Google Scholar
• Thompson AGB, Anastasiadis P, Druyeh R, Whitworth I, Nayak A, Nihat A, et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry. 2021;26:5955–66.
   PubMed Web of Science ®Google Scholar
• Wilke C, Reich S, van Swieten JC, Borroni B, Sanchez-Valle R, Moreno F, et al. Stratifying the presymptomatic phase of genetic frontotemporal dementia by serum NfL and pNfH: a longitudinal multicentre study. Ann Neurol. 2022;91:33–47.
   PubMed Web of Science ®Google Scholar